Heriberto Ramos
Corneal and Contact Management · Corpus Christi, TXNPI 1982697850
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.9%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Coopervision Inc. at 40.5% of the total. Reporting peaked in 2023 at $2,495 and has fallen 66.7% since, to $832 in 2025. Among corneal and contact management clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 109 payments — averaging $79.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coopervision Inc.$4K
- Alcon$2K
- Carl Zeiss Meditec USA, Inc.$900
- Biotissue Holdings Inc.$436
- Optos, Inc.$405
- Bausch & Lomb Americas Inc.$232
- plus $1000 from 11 others
What the payments were for
- Consulting fees$5006%
- Speaking & faculty fees$4,40051%
- Travel & lodging$1392%
- Food & beverage$3,46040%
- Gifts$781%
- Entertainment$711%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coopervision Inc. | 27 | $3,505 |
| Alcon | 20 | $2,171 |
| Carl Zeiss Meditec USA, Inc. | 1 | $900 |
| Biotissue Holdings Inc. | 5 | $436 |
| Optos, Inc. | 4 | $405 |
| Bausch & Lomb Americas Inc. | 9 | $232 |
| Sun Pharmaceutical Industries Inc. | 12 | $224 |
| Rxsight Inc | 2 | $140 |
| Tarsus Pharmaceuticals, Inc. | 4 | $123 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $98 |
| Harrow Eye, LLC | 5 | $84 |
| AbbVie(2 entities) | 4 | $78 |
| ABB Con-cise Optical Group LLC | 3 | $72 |
| Lombart Brothers, Inc. | 1 | $58 |
| Johnson & Johnson Vision Care, Inc. | 3 | $52 |
| Oyster Point Pharma, Inc. | 3 | $50 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MyDay Contact Lens$2,639
- Precision 1$1,000
- CIRRUS 6000 with AngioPlex$900
- CLARUS$900
- FORUM Glaucoma Workplace$900
- Humphrey Field Analyzer (HFA3)$900
- Retina Workplace$900
- TOTAL30$681
- PANORAMIC OPHTHALMOSCOPE$543
- DAILIES TOTAL1$500
- OCT OPHTHALMOSCOPE$271
- NFC-700$271
- Biofinity Contact Lens$226
- RXSIGHT CONTACT LENS$123
- RXSIGHT INJECTOR CARTRIDGE$123
- RXSIGHT INJECTOR HANDPIECE$123
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$123
- LIGHT ADJUSTABLE LENS (LAL)$123
- Multiple Brands Contact Lens$110
- MiSight Contact Lens$105
How this compares
$8,648 in reported general payments places this provider in the 90th percentile of 103 corneal and contact management providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 20 | $25,143 |
| Cyclosporine | 19 | $14,876 |
| LumiganBimatoprost | 30 | $9,499 |
| VyzultaLatanoprostene Bunod | 23 | $8,162 |
| Latanoprost | 17 | $110 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $78 | $34,64150 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $232 | $8,16223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 103 corneal and contact management providers in Texas.
Other corneal and contact management in Corpus Christi
- Maurice WilsonConroe$362K
- Roberto SaenzSan Antonio$171K
- Fariba ParmerGrapevine$26K
- Vissett SunHouston$13K
- Napoleon LoveroHouston$12K
- Sairah MalikHouston$10K
- Darlene JonesPlano$9K
- Glenn EllisorKingwood$7K
- Danny MalonePlano$7K
- Leigh GreenWaco$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.